Results 171 to 177 of about 15,373 (177)

A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer

Gynecologic Oncology, 2009
Rahel Ghebre, Melissa Geller, Patricia L Judson   +2 more
exaly  

Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2

European Journal of Cancer, 2018
Stephen Chia, Cortes J
exaly  

Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)

Annals of Oncology, 2007
Hans Wildiers, L Perey, D Köberle
exaly  

Fulvestrant (Faslodex®)—How to Make a Good Drug Better

Oncologist, 2007
John Robertson
exaly  

Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer

Journal of Steroid Biochemistry and Molecular Biology, 2017
Toru Hanamura, Toshifumi Niwa, Tatsuyuki Gohno   +2 more
exaly  

Fulvestrant and the sequential endocrine cascade for advanced breast cancer

British Journal of Cancer, 2004
exaly  

Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1)

Annals of Oncology, 2010
exaly